Evidence map›Paper›PMID 23117022›Full record

ReviewInternational journal of pharmaceutics2013

Recent advances in drug eluting stents.

Amey S Puranik, Eileen R Dawson, Nicholas A Peppas

Abstract readReview
In one paragraph

Review in International journal of pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Research progress of absorbable stents.International journal of medical sciences · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Bioclickable and mussel adhesive peptide mimics for engineering vascular stent surfaces.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amey S PuranikDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Eileen R Dawson
Nicholas A Peppas

Funding

pH Sensitive Complex Hydrogels for Protein Drug ReleaseR01EB000246 · NIBIB · UNIVERSITY OF TEXAS AUSTIN · PI LOWMAN, ANTHONY M, PEPPAS, NICHOLAS A · 2002 to 2014
$3.8M
Development of A Prepolarized MRI Extremity ScannerR01EB000346 · NIBIB · STANFORD UNIVERSITY · PI MACOVSKI, ALBERT · 2002 to 2004
$1.1M
NIBIB NIH HHS EB 1R01-000346-18NIBIB NIH HHS R01 EB000246
6 · The paper itself

Abstract

One of the most common medical interventions to reopen an occluded vessel is the implantation of a coronary stent. While this method of treatment is effective initially, restenosis, or the re-narrowing of the artery frequently occurs largely due to neointimal hyperplasia of smooth muscle cells. Drug eluting stents were developed in order to provide local, site-specific, controlled release of drugs that can inhibit neointima formation. By implementing a controlled release delivery system it may be possible to control the time release of the pharmacological factors and thus be able to bypass some of the critical events associated with stent hyperplasia and prevent the need for subsequent intervention. However, since the advent of first-generation drug eluting stents, long-term adverse effects have raised concerns regarding their safety. These limitations in safety and efficacy have triggered considerable research in developing biodegradable stents and more potent drug delivery systems. In this review, we shed light on the current state-of-the-art in drug eluting stents, problems related to them and highlight some of the ongoing research in this area.

Indexed as

Drug Delivery SystemsDrug-Eluting StentsAnimalsAtherosclerosisCoronary OcclusionCoronary RestenosisDelayed-Action PreparationsHumansNeointimaStentsDelayed-Action Preparations

Identifiers

PMID23117022
PMCPMC3567608

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.